Liavium™-CA1
(pregabalin chewable tablets)
LIAVIUM™-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-606.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling. See full prescribing information for complete dosing and administration instructions.
| Item # | Product Name | Supplied |
|---|---|---|
| 3003004 | Liavium-CA1 30 mg chewable tablets | 60 ct. bottle |
| 3003005 | Liavium-CA1, 90 mg chewable tablets | 60 ct. bottle |
| 3003006 | Liavium-CA1, 180 mg chewable tablets | 60 ct. bottle |
Active Ingredient(s): Pregabalin
IMPORTANT SAFETY INFORMATION:
Liavium-CA1 (pregabalin chewable tablets) is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-606. Liavium™-CA1 is a Schedule V controlled substance and should be handled and stored according to federal and state controlled-substance requirements. Based on publications in the scientific literature, the following adverse reactions are associated with administration of pregabalin in dogs: somnolence, increased appetite, decreased activity, increased water intake, decreased body temperature or hypothermia, ataxia and sedation. LIAVIUM™-CA1 has not been evaluated in dogs with renal disease.
Warnings: Not for use in humans. Keep out of reach of children. Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.
